Vaxcyte, Inc. (NASDAQ:PCVX) is highlighted as one of the best oversold NASDAQ stocks to buy now, with an Outperform rating maintained by Mizuho analyst Salim Syed. The firm’s pneumococcal vaccine candidates contain aluminum adjuvant, similar to those in Merck’s Vaxneuvance and Pfizer’s Prevnar 20, raising interest amidst reports of a potential review by HHS Secretary Kennedy.

Aluminum adjuvants are widely used in vaccines recommended by the CDC for infants and children since the 1930s. The FDA deems aluminum exposure from vaccines safe, with Mizuho stating that a review of licensed vaccines with aluminum adjuvants would affirm their safety. Vaxcyte’s innovative vaccine development aims to prevent bacterial infectious diseases.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines using advanced chemistry and modern synthetic techniques. While PCVX shows potential for investment, other AI stocks may offer more significant upside. Interested investors can explore a free report on the best short-term AI stock for further insights.

Read more at Yahoo Finance: Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)